Zimelidine — A serotonin uptake blocker in the treatment of phobic anxiety

Evans, Larry; Best, Jeannette; Moore, G. E.; Cox, John

doi:10.1016/0364-7722(80)90063-6

Cited by 43 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies with selective serotonin reuptake inhibitors (SSRIs) permit dissection and characterization of the mixed effect of imipramine on these neurotransmitter systems and facilitate exploration of the role of serotonin in the pathogenesis of PD. In accordance with the postulated role of serotonin in the mechanism of action underlying the effect of imipramine in PD, several open-label studies have shown similar beneficial effects with two selective uptake inhibitors, clomipramine and zimeldine (Evans et al, 1980;Gloger et al, 1981;Koczkas and Weissman, 1981;Grunhaus ei al., 1984). The results of several controlled studies with selective inhibitors of serotonin uptake confirm the antipanic efficacy of antidepressants and provide further evidence for the involvement of serotonin (Table 1).…”

Section: Serotonin Reuptake Inhibitorsmentioning

confidence: 64%

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

Boer¹,

Westenberg²

1995

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

The recognition that antidepressants are effective in panic and anxiety disorders had led to the evaluation of drugs selective for serotonin uptake in an attempt to dissect the neurotransmitters responsible for panic disorder. Fluvoxamine is the best studied of the selective serotonin reuptake inhibitors (SSRIs) and recent double-blind studies have confirmed earlier findings showing a reduced number and duration of panic attacks. In addition, fluvoxamine attenuates the 'accessory symptoms' of panic disorder such as depression and anxiety. Fluoxetine has only been evaluated in open trials, although these results are generally positive. Paroxetine has shown similar efficacy to clomipramine in a large, controlled study, although the other SSRIs have seldom been investigated. Fluvoxamine lacks the activating properties possessed by some SSRIs and this also makes it a useful candidate for the treatment of anxious depression. The efficacy of fluvoxamine in obsessive-compulsive disorder has been established in several double-blind, placebo-controlled trials. In clinical terms, fluvoxamine is approximately as effective as clomipramine, but with a decidedly better adverse event profile. Fluoxetine has also proved effective in obsessive-compulsive disorder, although a recent meta-analysis suggests that fluvoxamine may be somewhat more effective. The other SSRIs have not been sufficiently well studied to justify conclusive statements.

show abstract

Section: Serotonin Reuptake Inhibitorsmentioning

confidence: 64%

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

Boer¹,

Westenberg²

1995

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

show abstract

“…In general, the studies provide further positive evidence for the utility of the SSRI class in PD. Two open-label shortterm zimelidine treatment studies (Evans et al, 1980;Koczkas et al, 1981) showed promising antipanic effects in patients with PDA. Two follow-up doubleblind studies (Koczkas, 1983;Evans et al, 1986) indicated that zimelidine was more efficacious than placebo for the control of anxiety symptoms in PDA patients.…”

Section: Other Ssrismentioning

confidence: 99%

SSRIs in the treatment of panic disorder

Goddard

Charney

1998

Depress. Anxiety

View full text Add to dashboard Cite

“…Both delayed increases and immediate decreases in ethanol intake due to stress manipulations have been found [Rockman et al, 19871. Potential interactions of this stress variable with drug treatments may also be particularly relevant to the present work, since the drug classes to be used are active in anxiety paradigms [Chopin and Briley, 1987;Evans et al, 1980;Dunn et al, 19891. Home cage presentation of ethanol has been postulated to increase ethanol consumption [e.g., Wayner et al, 19721, a factor of significance in ethanol intake studies in which large amounts of ethanol are not always consumed.…”

Section: Experiments IImentioning

confidence: 99%

Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats

Knapp¹,

Benjamin²,

Pohorecky³

1992

Drug Development Research

View full text Add to dashboard Cite

Activation of 5-HT receptors via reuptake inhibition, precursor loading, or inhibition of catabolism have consistently resulted in decreases in ethanol preference in rats. The objective of the present studies was to determine whether activation of the EB-HT,~ receptor with gepirone, a selective agonist, decreases ethanol preference. Preference was first evaluated for ethanol solutions from 3 to 11 Yo, in a free-choice situation with ethanol solution or tapwater available in the home cage. Male Sprague-Dawley rats consumed the most ethanol solution relative to water at a concentration of 6%. When ethanol (6% solution) was available to ethanol-habituated rats in a 1 -hr restricted access situation, subjects consumed 5.9 * 0.4 ml. Pretreatment with gepirone (0.46-4.6 mg/kg IP) resulted in a dose-dependent reduction in ethanol consumption in the restricted-access paradigm. The 5-HT reuptake inhibitor fluoxetine also resulted in dose-related decreases in ethanol consumption in restricted access. A subsequent experiment using a lower dose of fluoxetine also found a suppressive effect on ethanol intake. A single daily dose of gepirone failed to decrease the consumption of 6% ethanol when it was continuously available in the home cage. The short half-life of gepirone might explain its lack of effect in continuous access with only one daily dose. Gepirone decreased open-field activity at higher (2.3 to 4.6-mg/kg) doses, but did not affect rotorod performance at any dose (4.6-9.2 mg/kg) tested, whereas haloperidol (0.025-1 .O mg/kg) significantly decreased time on the rotorod. These results suggest that 5-HT,, receptor activation decreases ethanol intake in limited access and that the motorically disrupting effects of gepirone are not manifest under these conditions. 0 1992 Wiley-Liss, Inc.

show abstract

Zimelidine — A serotonin uptake blocker in the treatment of phobic anxiety

Cited by 43 publications

References 8 publications

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

SSRIs in the treatment of panic disorder

Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats

Contact Info

Product

Resources

About